1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. AVALYN PHARMA INC.
Avalyn Pharma Inc.
XNAS: AVLN
Download real time
29.30 -1.32 (-4.31%)
New 52W High in past week
23,807.6
XNAS Volume

XNAS 15 May, 2026 9:41 AM (EDT)

Watchlist

Portfolio

Alert


Insider Trading disclosures for Avalyn Pharma Inc

The latest disclosure was made by Jill Carroll in Avalyn Pharma Inc where a trade of 277,778 Common Stock done at an average price of $18 was reported to US exchanges on May 1, 2026.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Jill Carroll Director Purchase of securities on an exchange or from another person at price $ 18.00 per share. 01 May 2026 277,778 2,186,562 - 18 5,000,004 Common Stock
Jill Carroll Director 01 May 2026 27,309,719 0 - - Series C-1 Convertible Preferred Stock
Jill Carroll Director 01 May 2026 1,419,298 1,419,298 - - Common Stock
Jill Carroll Director 01 May 2026 489,486 1,908,784 - - Common Stock
Jill Carroll Director 01 May 2026 9,418,561 0 - - Series D Convertible Preferred Stock
Douglas R. Carlson Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 29 Apr 2026 211,975 211,975 - - Stock Option (Right to Buy)
Jon Congleton Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 29 Apr 2026 26,978 26,978 - - Stock Option (Right to Buy)
Erin M. Lavelle Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 29 Apr 2026 26,978 26,978 - - Stock Option (Right to Buy)
Lyn Baranowski Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 29 Apr 2026 501,033 501,033 - - Stock Option (Right to Buy)
Melissa Rhodes Chief Operating Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 29 Apr 2026 211,975 211,975 - - Stock Option (Right to Buy)
Howard M. Lazarus Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 29 Apr 2026 211,975 211,975 - - Stock Option (Right to Buy)
Adam Golden General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 29 Apr 2026 254,891 254,891 - - Stock Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters